Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Delcath Systems, Inc. Market Cap
From what 6 stock analysts predict, the share price for Delcath Systems, Inc. (DCTH) might increase by 82.96% in the next year. This is based on a 12-month average estimation for DCTH. Price targets go from $18 to $25. The majority of stock analysts believe DCTH is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assigned DCTH 6 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Delcath Systems, Inc. to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on DCTH. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of DCTH.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $22 | Reiterates | Nov 11, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $22 | Reiterates | Oct 18, 2024 |
| John Newman Canaccord Genuity | Buy | $21 | Maintains | Oct 18, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $22 | Reiterates | Aug 6, 2024 |
| Sudan Loganathan Stephens & Co. | Overweight | $25 | Reiterates | Aug 6, 2024 |
| Chase Knickerbocker Craig-Hallum | Buy | $18 | Initiates | Jun 28, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $22 | Maintains | May 15, 2024 |
| Sudan Loganathan Stephens & Co. | Overweight | $25 | Initiates | May 14, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $20 | Maintains | Mar 27, 2024 |
| Arlinda Lee Canaccord Genuity | Buy | $21 | Maintains | Sep 7, 2023 |
| Marie Thibault BTIG | Buy | $20 | Maintains | Aug 16, 2023 |
| Scott Henry Roth MKM | Buy | $13 | Maintains | Aug 16, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $18 | Maintains | Aug 15, 2023 |
| Arlinda Lee Canaccord Genuity | Buy | $18 | Maintains | Aug 15, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $17 | Reiterates | May 24, 2023 |
Roth MKM | Buy | Maintains | Mar 28, 2023 | |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $17 | Maintains | Mar 28, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $19 | Maintains | Aug 10, 2022 |
| Marie Thibault BTIG | Buy | $20 | Maintains | Jun 24, 2022 |
HC Wainwright & Co. | Buy | Initiates | Dec 10, 2021 |
When did it IPO
2001
Staff Count
76
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Gerard J. Michel MBA, MS
Market Cap
$372.8M
In 2023, DCTH generated $2.1M in revenue, which was a decrease of -24.05% from the previous year. This can be seen as a signal that DCTH's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Delcath Systems, Inc. (NASDAQ: DCTH) announced that the FDA has completed its 30-day review of its IND application for a Phase 2 trial of HEPZATO™ for liver-dominant metastatic colorectal cancer.
Why It Matters - FDA approval for Delcath's Phase 2 trial of HEPZATO could enhance its market position and drive stock value, signaling potential advancements in cancer treatment.
Wed, 20 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Delcath reported Q3 US sales of $10 million, unlocking $25 million from Tranche B Warrants for Phase 2 trials. The HEPZATO KIT rollout is on track, with 15 centers by year-end and 30 by 2025.
Why It Matters - Delcath's rising sales and successful trials enhance its financial position and product validation, signaling growth potential and a stronger market presence, which can boost investor confidence.
Mon, 18 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Delcath Systems reported Q3 revenue of $11.2M, with an 85% gross margin. The company aims to expand from 12 to 30 treatment centers by 2025 and is exploring new cancer indications for HEPZATO.
Why It Matters - Strong Q3 earnings and significant revenue growth signal Delcath's expanding market presence and product potential, enhancing investor confidence in future profitability and stock performance.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Delcath Systems Inc (NASDAQ:DCTH) will hold its Q3 2024 earnings conference call on November 8, 2024, at 8:30 AM ET. Key executives will participate in the call.
Why It Matters - The upcoming earnings call will provide insights into Delcath Systems' financial performance and strategic direction, influencing stock price movements and investor sentiment.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Delcath Systems reported Q3 2024 revenues of $11.2 million, a 44% increase from Q2, with $10.0 million from HEPZATO KIT™ sales.
Why It Matters - Delcath's 44% revenue growth signals strong demand for its HEPZATO KIT™, potentially boosting investor confidence and indicating positive market momentum in oncology treatments.
Fri, 08 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Delcath Systems, Inc. (DCTH) reported a quarterly loss of $0.03 per share, better than the Zacks estimate of $0.13, and an improvement from a loss of $0.61 per share a year prior.
Why It Matters - Delcath's smaller-than-expected loss suggests improved financial performance, potentially boosting investor confidence and affecting stock valuation positively.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
